SCHEMBL3174622

SCHEMBL3174622

Nc1c(O)cc(C(=O)O)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.64
▸ CA1 P00915 3/20 0.64
▸ CA2 P00918 3/20 0.64
▸ CA7 P43166 3/20 0.64
▸ CA9 Q16790 3/20 0.64
▸ CA14 Q9ULX7 3/20 0.64
▸ MAPT P10636 3/20 0.64
▸ KDM4E B2RXH2 2/20 0.64
▸ CA4 P22748 2/20 0.64
▸ CA6 P23280 2/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ HPGD P15428 2/20 0.64
▸ MAPK1 P28482 2/20 0.64
▸ TDP1 Q9NUW8 2/20 0.64
▸ LMNA P02545 1/20 0.64
▸ TP53 P04637 1/20 0.64
▸ CA3 P07451 1/20 0.64
▸ SELL P14151 1/20 0.64
▸ SELP P16109 1/20 0.64
▸ FUT4 P22083 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3684356 0.88 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL7027788 0.84 TTR (0.59) CA12CA1CA2CA7CA9
SCHEMBL26176450 0.84 CA12 (0.52) CA12CA1CA2CA7CA9
SCHEMBL28902255 0.81 FASN (0.43) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL1325555 0.79 KDM4E (0.90) CA12CA1CA2CA7CA9
SCHEMBL4269298 0.78 CA12 (0.70) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL1845406 0.78 CA12 (1.00) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL678990 0.78 CA12 (1.00) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL4918056 0.78 CA12 (1.00) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL8088102 0.78 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112409197-B Gallic acid derivative with anti-inflammatory activity and preparation method and application thereof 宁波大学 2022-06-03 — — CN claimed
CN-112409197-A Gallic acid derivative with anti-inflammatory activity and preparation method and application thereof 宁波大学 2021-02-26 — — CN claimed
US-20200205541-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND L'OREAL (FR) 2020-07-02 — — US claimed
US-20130298933-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND L'OREAL (FR) 2013-11-14 — — US claimed
US-20100300472-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND L'OREAL S.A. (FR) 2010-12-02 — — US claimed
EP-4554549-A1 COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT OR CELLULOSE COMPOUND L'OREAL (FR) 2025-05-21 — — EP disclosed
CN-119677492-A Composition comprising a skin care active or a cellulose compound 莱雅公司 2025-03-21 — — CN disclosed
US-20250064703-A1 COMPOSITION COMPRISING SOLUBILIZED POLYPHENOL OREAL (FR) 2025-02-27 — — US disclosed
EP-4452205-A1 COMPOSITION COMPRISING SOLUBILIZED POLYPHENOL L'OREAL (FR) 2024-10-30 — — EP disclosed
CN-118542820-A Topical delivery system for active ingredients 莱雅公司 2024-08-27 — — CN disclosed
CN-118414140-A Compositions comprising dissolved polyphenols 莱雅公司 2024-07-30 — — CN disclosed
EP-4337159-A1 COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT AND TWO POLYGLYCERYL FATTY ACID ESTERS L'OREAL (FR) 2024-03-20 — — EP disclosed
WO-2017110151-A1 TOPICAL DELIVERY SYSTEM FOR ACTIVE INGREDIENTS L'OREAL (FR) 2017-06-29 — — WO disclosed
US-20170087064-A1 COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE L'OREAL (FR) 2017-03-30 — — US disclosed
US-20140326268-A1 PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS L'OREAL (FR) 2014-11-06 — — US disclosed
US-8765107-B2 Process for straightening keratin fibres with a heating means and denaturing agents L'OREAL (FR) 2014-07-01 — — US disclosed
US-20130298933-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND L'OREAL (FR) 2013-11-14 — — US disclosed
US-20120192888-A1 PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS L 'Oréal S.A., (FR) 2012-08-02 — — US disclosed
US-20100300472-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND L'OREAL S.A. (FR) 2010-12-02 — — US disclosed
US-20100028280-A1 PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS L'OREAL S.A. (FR) 2010-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120192888-A1 PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS KRT18, KRTCAP2, TUBB4A CA12 521/4885CA1 966/4885CA2 1658/4885
US-20200205541-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND KRT18, TUBB4A, TUBB4B CA12 1543/4885CA1 2454/4885CA2 2393/4885
US-20100028280-A1 PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS KRT18, KRTCAP2, TUBB4A CA12 521/4885CA1 966/4885CA2 1658/4885
US-20250064703-A1 COMPOSITION COMPRISING SOLUBILIZED POLYPHENOL PROC, GANC, LGALS1 CA12 777/4885CA1 1527/4885CA2 754/4885
US-20170087064-A1 COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE LRAT, LIPA, DAGLA CA12 4702/4885CA1 4833/4885CA2 4708/4885
US-20100300472-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND KRT18, TUBB4A, TUBB4B CA12 1543/4885CA1 2454/4885CA2 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback